Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.34 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953092 | 0.85 | CYP2C19 (0.38) | TSHRCYP2C19ARG1 | |
| SCHEMBL1053596 | 0.81 | CYP2C19 (0.45) | CYP2C19ARG1 | |
| SCHEMBL16211144 | 0.80 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL7421923 | 0.77 | CYP2C19 (0.40) | KMT2ACYP2C19ARG1EPHX1 | |
| SCHEMBL5809445 | 0.76 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL378774 | 0.75 | POLB (0.47) | KMT2A | |
| SCHEMBL14040657 | 0.74 | MC4R (0.41) | KDM4EKMT2A | |
| SCHEMBL4294182 | 0.74 | CYP2C19 (0.37) | GABRA5GABRB2GABRA1GABRA4GABRP | |
| SCHEMBL11346600 | 0.73 | CYP2C19 (0.52) | KMT2ACYP2C19ARG1EPHX1 | |
| SCHEMBL6586703 | 0.73 | CYP2C19 (0.52) | KMT2ACYP2C19ARG1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114007695-A | As AM2Heterocyclic spiro-compounds as receptor inhibitors | 谢菲尔德大学 | 2022-02-01 | — | — | CN | disclosed |
| WO-2020099885-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| CN-103619838-B | Piperidinyl monocarboxylic acids as S1P1 receptor agonists | 生物计划公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9266867-B2 | Piperidinyl monocarboxylic acids as S1P1 receptor agonists | BIOPROJET (FR) | 2016-02-23 | — | — | US | disclosed |
| EP-2697219-B1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2015-03-04 | — | — | EP | disclosed |
| EP-2697219-B1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET SOC CIV (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2014-04-10 | — | — | US | disclosed |
| CN-103619838-A | Novel piperidinyl monocarboxylic acids as s1p1 receptor agonists | BIOPROJET SOC CIV | 2014-03-05 | — | — | CN | disclosed |
| EP-2697219-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | Bioprojet (FR) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012140020-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012140020-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | BIOPROJET (FR) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140099316-A1 | NOVEL PIPERIDINYL MONOCARBOXYLIC ACIDS AS S1P1 RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | GABRA5 272/4885GABRB2 389/4885GABRA1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.